OncoMatch/Clinical Trials/NCT07138209
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Is NCT07138209 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including QLS32015 and Pomalidomide for relapsed or refractory multiple myeloma.
Treatment: QLS32015 · Pomalidomide · Selinexor · Dexamethasone — The purpose of this study is to compare the safety and efficacy of QLS32015 with Pd/Sd for the treatment of relapsed or refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Prior therapy
Must have received: proteasome inhibitor
Must have received: immunomodulatory drug
Must have received: anti-cd38 monoclonal antibody
Cannot have received: pomalidomide
Cannot have received: selinexor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify